Goldman Sachs analyst, Paul Choi, reiterated a Neutral rating on shares of Acceleron Pharma (NASDAQ: XLRN) but nearly doubled the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE